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Infection is a common complication in patients in intensive care units 
(ICUs) and is associated with considerable mortality and morbidity, 
and increased costs.[1] Antimicrobial treatment of patients with sepsis 
is increasingly complicated by the alarming rates of antimicrobial 
resistance (AMR) among pathogens. The ICU is often called the 
epicentre of AMR development owing to its extremely vulnerable 
population, with increased risks of becoming infected through 
multiple procedures and use of invasive devices.[2-4] Most large 
epidemiological studies of infection and sepsis in ICUs have been 
conducted in Europe, North America and Australia, with limited 
data from southern Africa.[1] With increasing AMR worldwide, it 
is crucial to monitor emerging trends in AMR at the local level to 
support clinical decision-making, infection control interventions 
and antimicrobial stewardship (AMS) strategies.[5,6] The most urgent 
and serious threats for the ICU include infections with extended-
spectrum beta-lactamase-producing (ESBL) Enterobacteriaceae, 
derepressed AmpC beta-lactamases and carbapenemases, extensively 
drug-resistant (XDR) and carbapenem-resistant Acinetobacter 
baumannii, multidrug-resistant (MDR) Pseudomonas aeruginosa, 
methicillin-resistant Staphylococcus aureus (MRSA), and azole-
resistant and MDR Candida spp.[7,8]
In its guide for the prevention of hospital-acquired infections, the 
World Health Organization[9] specifies that clinical microbiologists 
are responsible for providing annual reports of antimicrobial 
susceptibility patterns of pathogens. Epidemiological surveillance 
activities by microbiology laboratories are therefore growing in 
importance.[10,11] Monitoring of AMR trends is commonly performed 
in healthcare facilities using an annual summary of susceptibility 
rates, known as a cumulative antibiogram.[5,10] The most frequent 
use of a cumulative antibiogram report is to guide initial empirical 
antimicrobial therapy for the management of infections in patients 
who do not yet have definitive microbiological results to target 
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Background. Infection is a common complication for patients in intensive care units (ICUs), and increasing antimicrobial resistance 
(AMR) is a major concern. It is therefore crucial to monitor AMR patterns in order to support clinical decision-making and antimicrobial 
stewardship strategies. Clinical microbiologists should provide annual cumulative antibiogram reports, which can be used to guide initial 
empirical antimicrobial therapy for the management of infections.
Objectives. To analyse the cumulative antibiograms for the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) combined 
adult multidisciplinary ICU and high-care unit (HCU) for 2013 and 2017, compare the antimicrobial susceptibility testing (AST) patterns 
between the 2 years, and analyse the subset of blood culture isolates.
Methods. A retrospective descriptive analysis was performed of routine bacterial and fungal culture and AST data extracted from the 
National Health Laboratory Service laboratory information system for the ICU/HCU. Only the first diagnostic isolate of a given species per 
patient per year was included in the analysis. All analysis and reporting were done in accordance with the applicable Clinical and Laboratory 
Standards Institute guidelines.
Results. Enterobacteriaceae predominated in first-isolate cultures in 2013 (60%) and 2017 (56%). There was an overall decrease in 
extended-spectrum beta-lactamase-producing Enterobacteriaceae from 2013 (42%) to 2017 (30%) (p=0.013), accompanied by an increase 
in carbapenem-resistant Enterobacteriaceae from 2013 (4%) to 2017 (11%) (p=0.24). Although the total percentage of Acinetobacter spp. 
decreased in 2017 (p=0.021), the proportion of extensively drug-resistant isolates doubled to 68% in 2017 (p<0.001). The percentage 
of methicillin-resistant Staphylococcus aureus decreased significantly from 49% to 14% (p<0.001), along with a significant decrease in 
vancomycin-resistant enterococci from 17% to 0% (p=0.001). Candida auris increased from 0% in 2013 to 11% in 2017 (p=0.002), and non-
albicans Candida spp. predominated (80%) in blood cultures in 2017 (p=0.023).
Conclusions. Appropriate selection of  empirical  antimicrobial therapy should be guided by the ICU-specific antibiogram. The 
recommended empirical antimicrobial therapy at the CMJAH ICU/HCU based on the antibiogram analysis would include ertapenem to 
cover the Enterobacteriaceae. Amikacin is recommended for empirical treatment of suspected pseudomonal infections. Additional empirical 
antimicrobial therapy for Gram-positive organisms is not routinely advocated, and empirical antifungal therapy with amphotericin B or 
micafungin is only appropriate in patients at high risk for invasive candidiasis.
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treatment. The choice of empirical antimicrobial coverage is critical 
in the ICU because initiation of inadequate empirical therapy 
has been associated with poor clinical outcomes.[3,12] Bloodstream 
infections represent a common complication among critically ill 
patients in the ICU, and a leading cause of morbidity and mortality. 
Early appropriate antibiotic therapy is therefore a critically important 
aspect of the treatment of these patients.[13] Cumulative antibiograms 
have additional applications, including updating periprocedural or 
perioperative prophylaxis recommendations, providing a rationale 
for antimicrobial formulary selection, surveying local resistance 
patterns, and identifying targets for AMS and best practices.[10,14]
No cumulative antibiogram studies have yet been published 
from the Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH) adult ICU and high-care unit (HCU), or any other 
ICUs in South Africa (SA). This study was designed to provide the 
necessary cumulative antibiograms for the CMJAH ICU/HCU, and 
to demonstrate AMR changes and trends between two time periods. 
In 2017 the SA National Department of Health mandated the 
implementation of AMS interventions at healthcare facilities in order 
to combat the emerging threat of AMR. Emergence of antibiotic 
resistance is highly correlated with selective pressure resulting from 
excessive use of antimicrobials in the ICU. It is therefore crucial for 
ICU clinicians to have regularly updated antibiograms in order to 
make informed decisions about empirical antibiotic choices.
Objectives
The primary study objectives were to prepare and analyse the 
cumulative antibiograms for the ICU/HCU for the years 2013 and 
2017, and to compare the different organisms isolated and their 
antimicrobial susceptibility testing (AST) patterns between the 
2 years. The secondary objective was to specifically analyse the 
cumulative antibiogram data for the subset of blood culture isolates.
Methods
Study setting
CMJAH is an academic tertiary-level hospital with a 12-bed 
multidisciplinary ICU and an 8-bed HCU. Adult patients admitted 
to these units frequently have severe sepsis and multiple organ 
dysfunction with or without septic shock, or have recently undergone 
complex surgery.[15]
Study design
A retrospective descriptive analysis of all the routine bacterial and 
fungal culture and AST data from the CMJAH ICU/HCU was 
performed. All the data were extracted from the National Health 
Laboratory Service (NHLS) laboratory information system (LIS). 
Culture and AST data from 1 January 2013 to 31 December 2013 
were compared with data from 1 January 2017 to 31 December 2017. 
Clinical samples were tested at the NHLS microbiology laboratory 
based at CMJAH. The laboratory used a variety of identification 
and AST methodologies, which included the manual Kirby-Bauer 
disc diffusion test and the Etest (bioMérieux, France), as well as the 
automated Microscan (Beckman Coulter Inc., USA) and Vitek 2 
(bioMérieux, France). AST results were interpreted according to the 
contemporary Clinical and Laboratory Standards Institute (CLSI) 
guidelines.[16,17] Molecular confirmation of carbapenemase production 
was performed at the Antimicrobial Resistance Laboratory at the 
National Institute for Communicable Diseases from 2014 onwards.
CLSI guideline CLSI M39-A4[14] was used to guide the compilation 
of the cumulative antibiograms, as it provides criteria for standardising 
and benchmarking antibiograms. To eliminate the bias inherent in 
an ‘all-isolates’ approach, only the first diagnostic isolate of a given 
species per patient per analysis period was included, as this approach 
has direct relevance to guiding recommendations for initial empirical 
therapy. Culture and susceptibility reports from samples collected for 
surveillance or screening were excluded.
Definitions
First isolate refers to the initial microbial isolate of a particular species 
recovered from a patient during the time period analysed, regardless 
of body source, specimen type or AST profile.[14]
Susceptible refers to a category where isolates are inhibited by the 
usually achievable concentrations of antimicrobial agent when the 
dose recommended to treat the site of infection is used.[14]
Susceptible dose dependent means that the isolate’s minimum 
inhibitory concentration is high, but increased dosing of the agent 
has the potential to inhibit the yeast in vivo.[14]
Non-susceptible is a category used for isolates that are not 
inhibited by the usually achievable concentrations of antimicrobial 
agent with the normal dosage schedules, and includes intermediate 
and resistant.[14]
AmpC. For the Enterobacteriaceae, non-susceptibility to cefoxitin 
was used as a marker of inducible ampicillin class C beta-lactamase 
production.[18]
ESBL. Non-susceptibility to third- and/or fourth-generation 
cephalosporins was used to predict ESBL production.[16,17]
CRE. Non-susceptibility to any of the carbapenems was a marker of 
carbapenem-resistant Enterobacteriaceae (CRE). Non-susceptibility 
to carbapenems may be the result of various mechanisms, including 
production of carbapenemases or combinations of AmpC, ESBL and 
porin loss.[16,17]
CPE. Only Enterobacteriaceae with a confirmed carbapenemase-
producing gene were defined as carbapenemase-producing 
Enterobacteriaceae (CPE).[16,17]
MDR and XDR. Definitions of MDR and XDR were applied 
from Magiorakos et al.[19] to report on the AST resistance profiles of 
Acinetobacter spp. and Pseudomonas spp.
Statistical analysis
Statistical analyses were performed using Excel version 2010 (Micro-
soft Corporation, USA) and GraphPad version 8.0 (Graphpad Software, 
USA). Categorical data were presented as percent susceptibility for 
each antimicrobial agent tested. The Agresti-Coull method was used 
to calculate confidence intervals, and Fisher’s exact test to compare 
differences between the two observed percent susceptible estimates 
from 2013 v. 2017. The p-values were reported as two-tailed, and 
values <0.05 were considered statistically significant.
Ethical approval
The study was approved by the Human Research Ethics Committee, 
University of the Witwatersrand (ref. no. W-CBP-180802-3).
Results
Analysis of first isolates
Of the 594 first-isolate cultures in 2013, 53% (n=314) were Gram-
negative bacteria, 33% (n=196) were Gram-positive bacteria and 
14% (n=84) were Candida spp. In 2017, 59% (n=388) of the 662 
first-isolate cultures were Gram-negative bacteria, 30% (n=200) 
were Gram-positive bacteria and 11% (n=74) were Candida spp. The 
increase in the proportion of Gram-negative bacteria from 53% in 
2013 to 59% in 2017 was statistically significant (p=0.046). Numbers 
of anaerobic organisms isolated in both 2013 (Bacteroides spp., 
n=2) and 2017 (Bacteroides spp., n=12) were low. Table 1 shows the 
distribution of all the first isolates by culture site.
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Enterobacteriaceae
The Enterobacteriaceae made up the largest proportion of first-
isolate cultures in 2013 (60%) and 2017 (56%) (Table 2). Among the 
Enterobacteriaceae isolated in 2013 and 2017, there were three main 
genera: Klebsiella spp., Escherichia spp. and Enterobacter spp. In the 
panel of antimicrobial agents tested, the only significant change was 
an overall decrease in susceptibility to piperacillin-tazobactam from 
75% in 2013 to 64% in 2017 (p=0.017). The statistically significant 
Table 1. Distribution of all the first isolates by culture site, 2013 v. 2017
2013 2017 2013 v. 2017,  
p-valueCulture site/specimen Total isolates, n (%) 95% CI Total isolates, n (%) 95% CI
Blood culture 158 (27) 23 - 30 254 (38) 35 - 42 <0.001*
Intravenous catheter tips 53 (9) 7 - 12 27 (4) 3 - 6 <0.001*
Pus, sterile fluid and tissue 156 (26) 23 - 30 168 (25) 22 - 29 0.747
Respiratory tract 156 (26) 23 - 30 156 (24) 20 - 27 0.295
Urine 70 (12) 9 - 15 57 (9) 7 - 11 0.075
Cerebrospinal fluid 1 (<1) 0 - 2 0 0 - 1 0.473
CI = confidence interval.
*Statistically significant (p<0.05).
Table 2. Summary of the total and resistant Gram-negative isolates (first-isolate results), 2013 v. 2017
Organism
2013 2017
2013 v. 2017, 
p-value
n isolates 
(% of 
total†)
n isolates 
(% of 
group‡)
n (%) 
resistant 
isolates 95% CI
n isolates 
(% of 
total†)
n isolates 
(% of 
group‡)
n (%) 
resistant 
isolates 95% CI
Total Enterobacteriaceae 187 (60) 54 - 65 219 (56) 51 - 61 0.442
Total AmpC 29 (16) 11 - 21 27 (12) 9 - 17 0.388
Total ESBL 79 (42) 35 - 49 66 (30) 24 - 37 0.013*
Total CRE 8 (4) 2 - 8 23 (11) 7 - 15 0.024*
Klebsiella spp. 69 (37) 30 - 44 85 (39) 33 - 45 0.758
AmpC 3 (4) 1 - 13 4 (4) 1 - 10 1.000
ESBL 42 (61) 49 - 72 30 (34) 25 - 45 0.001*
CRE 4 (6) 2 - 14 16 (18) 11 - 27 0.029*
Escherichia coli 58 (31) 25 - 38 69 (32) 26 - 38 1.000
AmpC 2 (3) 0 - 12 3 (3) 0 - 11 1.000
ESBL 17 (29) 19 - 42 23 (32) 22 - 44 0.848
CRE 1 (2) 0 - 10 0 (0) 0 - 6 0.457
Enterobacter spp. 30 (16) 11 - 22 34 (16) 11 - 21 0.892
AmpC 10 (33) 19 - 51 15 (41) 26 - 58 0.801
ESBL 7 (23) 12 - 41 10 (26) 14 - 43 0.193
CRE 0 (0) 0 - 13 7 (18) 8 - 34 0.483
Other Enterobacteriaceae§ 30 (16) 11 - 22 31 (14) 10 - 19 0.676
AmpC 10 (33) 19 - 51 9 (26) 13 - 43 0.582
ESBL 7 (23) 12 - 41 7 (19) 9 - 37 0.762
CRE 0 (0) 0 - 13 3 (6) 1 - 22 0.492
Total non-fermentative GNB 124 (39) 34 - 45 149 (38) 34 - 43 0.815
Acinetobacter spp. 65 (52) 44 - 61 57 (38) 31 - 46 0.021*
MDR 41 (62) 49 - 72 9 (14) 7 - 26 <0.001*
XDR 23 (34) 23 - 46 40 (68) 55 - 79 <0.001*
Pseudomonas spp. 52 (42) 34 - 51 65 (44) 36 - 52 0.807
MDR 8 (13) 6 - 26 7 (9) 4 - 19 0.559
XDR 1 (0) 0 - 8 5 (6) 2 - 15 0.128
Total non-fermenters¶ 7 (6) 3 - 11 27 (18) 13 - 25 0.002*
Burkholderia spp. 3 (2) 1 - 7 21 (14) 9 - 21 <0.001*
Total GNB‖ 314 (53) 49 - 57 388 (59) 55 - 62 0.046*
CI = confidence interval; ESBL = extended-spectrum beta-lactamase; CRE = carbapenem-resistant Enterobacteriaceae; MDR = multidrug-resistant; XDR = extensively drug-resistant;  
GNB = Gram-negative bacilli.
*Statistically significant (p<0.05).
†Total GNB.
‡Groups are: total Enterobacteriaceae, total non-fermentative GNB.
§2013: Proteus spp. (n=10), Serratia spp. (n=7), Citrobacter spp. (n=6), Morganella morganii (n=5), Providencia stuartii (n=1), Salmonella spp. (n=1); 2017: Proteus spp. (n=12), M. morganii (n=9),  
Citrobacter spp. (n=5), Serratia marcescens (n=1), Hafnia alvei (n=1), Salmonella spp. (n=1), Raoultella ornithinolytica (n=1), Pantoa spp. (n=1).
¶2013: Stenotrophomonas maltophilia (n=5), Burkholderia cepacia (n=2); 2017: S. maltophilia (n=6), Burkholderia spp. (n=21).
‖2013: Bacteroides spp. (n=2), Haemophilus influenzae (n=1) were additional Gram-negatives added to total; 2017: Bacteroides spp. (n=12), H. influenzae (n=8) were additional Gram-negatives added 
to total.
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decrease in ESBL-producing isolates from 42% in 2013 to 30% in 
2017 (p=0.013) was accompanied by a significant increase in the 
proportion of CRE from 4% in 2013 to 11% in 2017 (p=0.024). Only 
4 of the 8 CRE were sent for genotyping in 2013, of which 1 was a 
blaVIM, 1 was a blaIMP, and 2 tested negative for carbapenemase genes. 
In 2017, 21 of the 23 CRE were sent for genotyping. The predominant 
carbapenamase was blaOXA-48 and its variants (n=17). Three blaNDM and 
1 blaVIM were also detected.
Klebsiella spp. were the most frequent Gram-negative bacteria 
isolated in both years. In 2013, 61% of all Klebsiella spp. were ESBL 
producers, and this decreased to 34% in 2017 (p=0.001) owing to 
the accompanying increase in CRE from 6% in 2013 to 18% in 2017 
(p=0.029). In comparison with 2013, Klebsiella spp. demonstrated 
higher susceptibility to amoxicillin-clavulanic acid (p=0.008), cefepime 
(p=0.03) and trimethoprim-sulfamethoxazole (p=0.006) in 2017 
(Fig. 1A). Of the aminoglycosides, Klebsiella spp. were most susceptible 
to amikacin in both years. In 2013 and 2017, >50% of the Klebsiella spp. 
were non-susceptible to third-generation cephalosporins. Klebsiella 
spp. were all susceptible to tigecycline in 2017, but no comparison 
could be made with 2013 as tigecycline was not tested.
Of the Enterobacteriaceae, E. coli was the second most prevalent 
organism isolated in both years (Table 2). Susceptibility to the 
third- and fourth-generation cephalosporins was >60% (Fig. 1B). 
Amikacin was the most susceptible aminoglycoside for E. coli. 
The only antimicrobial agents with susceptibilities <50% in both 
years were ampicillin, amoxicillin-clavulanic acid and trimethoprim-
sulfamethoxazole.
Enterobacter spp. were the third most frequently isolated 
Enterobacteriaceae in the study years. Enterobacter spp. produce 
an inducible AmpC beta-lactamase, and expression of this enzyme 
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Fig. 1. Percentage of Enterobacteriaceae isolates susceptible to routinely tested antimicrobial agents, 2013 v. 2017. (*Statistically significant differences in 
percentage susceptibility between 2013 and 2017.)
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confers resistance to broad-spectrum cephalosporins including 
cefotaxime, ceftazidime and ceftriaxone. More than 50% of the 
isolates were susceptible to the fourth-generation cephalosporin 
cefepime (Fig. 1C). Again, amikacin was the most susceptible 
aminoglycoside for the Enterobacter spp.
The remaining Enterobacteriaceae that were isolated had <30 
isolates per genus, and were therefore grouped together as ‘other 
Enterobacteriaceae’ for the purposes of analysis. In this group, 
>80% of isolates were susceptible to the aminoglycosides, as well as 
ciprofloxacin, in both 2013 and 2017 (Fig. 1D).
Non-fermentative Gram-negative bacteria
In 2013, Acinetobacter spp. were the predominant non-fermenters 
(52%), followed by Pseudomonas spp. (42%) (Table 2). In contrast, 
in 2017, Pseudomonas spp. predominated (44%), followed by 
Acinetobacter spp. (38%). The remaining non-fermentative Gram-
negative bacteria isolated had numbers <30 per genus. However, 
owing to their intrinsic MDR, they were included in the analysis. In 
2013, 5 Stenotrophamonas maltophilia and 2 Burkholderia cepacia 
were isolated, and in 2017, 21 Burkholderia spp. and 6 S. maltophilia 
were isolated.
The overall reduction in the number of Acinetobacter spp. in 
2017 was statistically significant (p=0.021). In 2013, 62% were MDR 
compared with only 14% in 2017 (p<0.0001). This decrease was due 
to the significant doubling of the percentage of XDR Acinetobacter 
spp., from 34% in 2013 to 68% in 2017 (p<0.001). There was a 
significant increase in non-susceptibility in 2017 to ceftazidime 
(p=0.008), gentamicin (p=0.016) and tobramycin (p<0.001) (Fig. 2A). 
In 2017, >60% of all antimicrobials tested were non-susceptible 
for Acinetobacter spp., and susceptibility to the carbapenems, 
meropenem and imipenem, was <20%. Tigecycline was susceptible 
in 89% of Acinetobacter spp. in 2017, but no comparison could be 
made with 2013 as tigecycline was not tested.
There were limited changes in Pseudomonas spp. between 
the 2 study years. A significant reduction in the susceptibility of 
piperacillin-tazobactam was observed, from 92% in 2013 to 78% 
in 2017 (p=0.04) (Fig. 2B). There was a significant increase in the 
number of Burkholderia spp. from 2013 to 2017 (p<0.001). Both 
S. maltophilia and Burkholderia spp. had very high non-susceptibility 
rates to multiple antimicrobials (>69%) (Fig. 2C), which is in keeping 
with their intrinsically resistant phenotype.
Gram-positive bacteria
Of the 196 Gram-positive bacteria isolated in 2013, 58% were 
Staphylococcus spp. and 37% were Enterococcus spp. (Table 3). 
Similarly, in 2017, of the 200 Gram-positive bacterial isolates, 64% 
were Staphylococcus spp. and 28% were Enterococcus spp. For the 
remaining 5% (n=10) of Gram-positive organisms isolated in 2013 
and 8% (n=16) in 2017, AST analysis was omitted owing to the small 
number of isolates.
Staphylococcus spp. made up the largest proportion of the first-
isolate Gram-positive cultures in both 2013 (n=114) and 2017 
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Fig. 2. Percentage of non-fermentative Gram-negative bacteria susceptible to routinely tested antimicrobial agents, 2013 v. 2017. (*Statistically significant 
differences in percentage susceptibility between 2013 and 2017.)
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(n=128). The proportion of MRSA decreased significantly in 2017 
to 14% (p<0.001). Additionally, the susceptibility of S. aureus to 
rifampicin also increased significantly in 2017 (p=0.005) (Fig.  3A). 
All S. aureus isolates were susceptible to vancomycin and linezolid in 
both study years. The vast majority of methicillin-resistant coagulase-
negative staphylococci (CoNS) were resistant to cloxacillin. However, 
there was a significant reduction in the proportion of methicillin-
resistant CoNS, from 83% in 2013 to 72% in 2017 (p=0.016) (Fig. 3B). 
The susceptibility of CoNS to trimethoprim-sulfamethoxazole also 
increased significantly in 2017 (p=0.028).
E. faecium predominated in both years, and consequently only one-
third of Enterococcus spp. were susceptible to ampicillin (Fig.  3C). 
In 2013, 17% of the Enterococcus spp. isolated were vancomycin-
resistant enterococci (VRE). This reduced significantly in 2017, when 
no VRE were isolated (p=0.001). All the Enterococcus spp. in both 
study years were susceptible to linezolid.
Candida spp.
Table 4 summarises the different Candida spp. isolated in both 
the study years. C. albicans was the predominant species isolated 
in both 2013 (64%) and 2017 (65%). C. albicans remained 100% 
susceptible to the two routinely tested azole antifungals, fluconazole 
and voriconazole, in both years. There were two significant changes 
in the species distribution in the study years: C. parapsilosis decreased 
Table 3. Summary of the total and resistant Gram-positive isolates (first-isolate results), 2013 v. 2017
2013 2017
2013 v. 
2017, 
p-valueOrganism
n isolates 
(% of 
total†)
n isolates 
(% of 
group‡)
n (%) 
resistant 
isolates 95% CI
n isolates 
(% of 
total†)
n isolates 
(% of 
group‡)
n (%) 
resistant 
isolates 95% CI
Total Staphylococcus spp. 114 (58) 51 - 65 128 (64) 57 - 70 0.257
S. aureus 49 (43) 34 - 52 44 (34) 27 - 43 0.187
MRSA 24 (49) 36 - 63 6 (14) 6 - 27 <0.001*
Coagulase-negative staphylococcus 65 (57) 48 - 66 84 (66) 57 - 73 0.078
MR CoNS 54 (83) 72 - 90 54 (72) 54 - 74 0.016*
Total Enterococcus spp. 72 (37) 30 - 44 56 (28) 22 - 35 0.068
E. faecalis 20 (28) 19 - 39 19 (34) 23 - 47 0.562
E. faecium 50 (69) 58 - 79 36 (64) 51 - 76 0.573
VRE 12 (17) 10 - 27 0 (0) 0 - 8 0.001*
Other Gram-positive cocci§ 10 (5) 3 - 9 16 (8) 5 - 13 0.311
Total Gram-positive cocci 196 (33) 29 - 37 200 (30) 27 - 34 0.301
CI = confidence interval, MRSA = methicillin-resistant S. aureus, MR CoNS = methicillin-resistant coagulase-negative staphylococcus, VRE = vanvomycin-resistant enterococcus.
*Statistically significant (p<0.05).
†Total Gram-positive cocci.
‡Groups are: total Staphylococcus spp., total Enterococcus spp., other Gram-positive cocci.
§2013: Streptococcus agalactiae (n=1), S. anginosus (n=3), S. pneumoniae (n=2), S. pyogenes (n=1), S. viridans (n=3); 2017: S. anginosus (n=5), S. pneumoniae (n=4), S. viridans (n=7).
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Fig. 3. Percentage of Gram-positive isolates susceptible to routinely tested antimicrobial agents, 2013 v. 2017. (*Statistically significant differences in percentage 
susceptibility between 2013 and 2017.)
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from 7% in 2013 to 0% in 2017 (p=0.030), and C. auris increased from 
0% in 2013 to 11% in 2017 (p=0.002). Overall susceptibility of non-
albicans Candida spp. (NAC) to the azole antifungals remained <50% 
for both years (Fig. 4). Micafungin and amphotericin B were 100% 
susceptible in 2017, but no comparison could be made with 2013, when 
these antifungals were not tested.
Analysis of bloodstream isolates
Table 5 summarises the first-isolate organisms from blood cultures. 
Of the Gram-negative blood culture isolates, the Enterobacteriaceae 
predominated in both 2013 (62%) and 2017 (55%). All the members 
of the Enterobacteriaceae isolated each year were analysed together 
as a group to allow for sufficient numbers. Klebsiella spp., E. coli 
and Enterobacter spp. were found to be the predominant species 
in both years. There was an overall decrease in ESBL-producing 
Enterobacteriaceae from 52% in 2013 to 32% in 2017 (p=0.032). Of all 
the antimicrobial agents tested, there was only a significant increase 
in susceptibility for gentamicin, from 41% in 2013 to 63% in 2017 
(p=0.013).
All the non-fermentative Gram-negative bacteria isolated each year 
were analysed together as a group to allow for sufficient numbers. In 
2013, 29% of the non-fermenters were MDR compared with 9% in 
2017 (p=0.005); however, there was a non-significant increase in the 
percentage of XDR non-fermenters from 29% in 2013 to 37% in 2017. 
A significant decrease in the susceptibility of tobramycin from 54% in 
2013 to 19% in 2017 (p=0.005) was noted, and there was a significant 
increase in the proportion of Burkholderia spp. from 3% in 2013 to 24% 
in 2017 (p=0.009).
Of the Gram-positive bacteria isolated from blood cultures, CoNS 
predominated in both 2013 (54%) and 2017 (60%). There was a 
significant reduction in the proportion of methicillin-resistant CoNS, 
from 83% in 2013 to 62% in 2017 (p=0.040).
Of all the Candida spp. isolated from blood cultures in 2013, 
C. albicans was the predominant species isolated (58%); however, 
in 2017 the NAC predominated (80%), and this difference was 
statistically significant (p=0.023). In keeping with this change, there 
was a significant reduction in overall susceptibility of the bloodstream 
Candida spp. to fluconazole, from 63% in 2013 to 20% in 2017 (p=0.01).
Discussion
This is the first study describing the cumulative antibiogram results 
for the CMJAH multidisciplinary adult ICU and HCU. The findings 
from this study provide important epidemiological information. The 
pertinent findings include the predominance of Enterobacteriaceae 
in 2013 and 2017. Of concern was the overall increase in CRE, XDR 
A. baumannii and Burkholderia spp. The significant reduction in both 
MRSA and VRE is noteworthy. Among the Candida spp. isolated, 
the emergence of MDR C. auris and a predominance of NAC in 
bloodstream isolates in 2017 reflects current global epidemiology.[20]
The ESKAPE pathogens (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, Enterobacter spp.) represent the six most common MDR 
pathogens threatening patients in ICUs globally.[21] These pathogens 
were also prevalent bacterial isolates in the CMJAH ICU/HCU. The 
predominance of Enterobacteriaceae in this unit is similar to the 
findings of the global EPIC II study.[1] The decrease in the proportion 
of ESBL-producing Enterobacteriaceae was coupled with a significant 
increase in the proportion of CRE from 4% to 11%, a finding that 
could not be corroborated by other studies. The majority of the CPE 
(65%) were Klebsiella spp., and the predominant carbapenamase was 
blaOXA-48 and its variants (81%), which is in keeping with published 
national surveillance data from SA.[22,23] The number of blaOXA-48 
isolates may underestimate the true prevalence in this unit, as blaOXA-48 
isolates could have appeared susceptible to carbapenems on routine 
AST and would therefore not have been sent for genotyping.[22]
Also in keeping with published data, Klebsiella spp. were the 
most frequent Gram-negative bacteria isolated in both years.[23] 
Despite the overall ESBL decrease, Klebsiella spp. remained the 
predominant ESBL-producing Enterobacteriaceae in both years. 
The reasons for the increase in susceptibility of three antimicrobials 
in 2017, amoxicillin-clavulanic acid, cefepime, and trimethoprim-
sulfamethoxazole, are not known. The CLSI cefepime breakpoints 
were lowered between 2013 and 2017, so an increase in cefepime 
resistance would have been expected over the study years.[16,17] Strain 
Table 4. Summary of the Candida spp. isolated (first-isolate results), 2013 v. 2017
  2013 2017 2013 v. 2017,  
p-valueOrganism Total n (%) isolates 95% CI Total n (%) isolates 95% CI
C. albicans 54 (64) 54 - 72 48 (65) 53 - 75 1.000
Non-albicans Candida spp. 30 (36) 26 - 46 26 (35) 25 - 47 1.000
C. auris 0 (0) 0 - 5 8 (11) 2 - 20 0.002*
C. glabrata 11 (13) 7 - 22 11 (15) 8 - 25 0.820
C. krusei 4 (5) 2 - 12 4 (5) 2 - 14 1.000
C. parapsilosis 6 (7) 3 - 15 0 (0) 0 - 6 0.030*
C. tropicalis 3 (4) 1 - 10 2 (3) 0 - 10 1.000
Other Candida spp. 6 (7) 3 - 15 1 (1) 0 - 8 0.122
Total Candida 84 (14) 12 - 17 74 (11) 9 - 14 0.125
CI = confidence interval.
*Statistically significant (p<0.05).
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Fig. 4. Percentage of non-albicans Candida spp. susceptible to routinely 
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inhibit the yeast in vivo.)
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typing of the Klebsiella spp. between the different time points may be 
a useful tool to assist with understanding changes in antibiograms, 
but this would require isolates to be stored for prospective analysis. 
Imipenem and meropenem had the highest susceptibilities (97 - 98%) 
of all the antimicrobial agents tested in both years. Ertapenem still 
had high susceptibility rates (93%) and would therefore be the most 
appropriate choice for empirical treatment of Enterobacteriaceae in 
cases of suspected nosocomial infection. For patients in septic shock 
with a suspected CRE infection, combination empirical therapy 
is associated with improved survival.[24] The addition of amikacin 
would be recommended, as among the CRE in 2017 specifically, 83% 
(19/23) of the isolates were susceptible to amikacin.
The overall prevalence of non-fermentative Gram-negative 
bacteria did not differ between the study years. There was, however, 
a significant increase in Burkholderia spp. over the 2 years, with most 
isolates (71%) being recovered from blood culture. This trend has also 
been seen elsewhere in ICU patients without cystic fibrosis.[25] There 
was a surprising decrease in the overall percentage of Acinetobacter 
spp. These bacteria can be found in the natural environment as well 
as occurring as commensals of the skin and body secretions. The 
true prevalence of infection caused by Acinetobacter spp. is difficult 
to assess, as there are no guidelines to assist in differentiating 
between isolates that cause infection v. colonisation.[26] The increasing 
resistance of Acinetobacter spp. from 2013 to 2017 was evidenced by 
the doubling of XDR isolates in 2017. This increasing resistance is 
also in keeping with local and international published data.[23,26]
Susceptibility patterns of Pseudomonas spp. remained stable over the 
2 study years, with a significant decrease only in the susceptibility of 
piperacillin-tazobactam, to <80%, making this agent inappropriate 
for the empirical therapy of nosocomial Pseudomonas spp. infections. 
The carbapenems were the least susceptible antimicrobials tested for 
Pseudomonas spp. Amikacin had the highest susceptibility (94%) of 
all the antimicrobial agents tested in 2017, and would therefore be 
the agent of choice for empirical treatment of suspected nosocomial 
pseudomonal infections.
Susceptibility of Acinetobacter spp. to the carbapenems was very 
low (<20%), but remained constant, and susceptibility was highest to 
tigecycline in 2017. For the non-fermenters on blood cultures, there 
was a very high non-susceptibility rate to the panel of antimicrobials 
tested, and in 2017, the most susceptible agent was ceftazidime at 
62%. Empirical therapy with meropenem or imipenem will not 
provide adequate cover for either Acinetobacter spp. or Pseudomonas 
spp. For Acinetobacter spp. infections assessed as clinically significant, 
optimal therapy will probably require the use of colistin for patients 
with septic shock. However, reliable colistin AST was not available 
during the study years.[23] New AST methods for colistin (broth 
microdilution) have been implemented in the laboratory, and colistin 
AST results would need to be studied going forward.
Among the Gram-positive isolates, Staphylococcus spp. pre-
dominated in both study years. CoNS are normal skin commensals 
and are frequently isolated from clinical specimens. Determining 
whether an isolate of CoNS represents a true infection or colonisation 
Table 5. Summary of bloodstream isolates (total and resistant), 2013 (N=178) v. 2017 (N=270)
2013 2017
2013 v. 
2017, 
p-valueOrganism
n isolates 
(% of 
total†)
n isolates 
(% of 
group‡)
Resistant 
isolates, n (%) 95% CI
n isolates 
(% of 
total†)
n isolates 
(% of 
group‡)
Resistant 
isolates, n (%) 95% CI
Total Enterobacteriaceae§ 56 (62) 51 - 71 77 (55) 47 - 63 0.343
ESBL 29 (52) 39 - 64 25 (32) 23 - 44 0.032*
CRE 4 (7) 2 - 17 7 (9) 4 - 18 0.760
Total non-fermentative GNB¶ 35 (38) 29 - 49 63 (45) 37 -53 0.343
MDR 10 (29) 16 - 45 4 (9) 3 - 21 0.005*
XDR 10 (29) 16 - 45 17 (37) 24 - 51 1.000
Burkholderia spp. 1 (3) 0 - 16 15 (24) 15 - 36 0.009*
Total GNB 91 (51) 44 - 58 140 (52) 46 - 58 0.923
Total Staphylococcus spp. 44 (66) 54 - 76 86 (78) 70 - 85 0.080
S. aureus 8 (12) 6 - 22 20 (18) 12 - 27 0.653
MRSA 3 (38) 13 - 70 2 (2) 0 - 7 0.335
CoNS 36 (54) 42 - 65 66 (60) 51 - 69 0.653
MR CoNS 30 (83) 68 - 93 41 (62) 29 - 47 0.040*
Total Enterococcus spp. 23 (34) 24 - 46 24 (22) 15 - 30 0.080
VRE 2 (9) 1 - 28 0 (0) 0 - 4 0.234
Total GPC 67 (38) 31 - 45 110 (41) 35 - 47 0.554
Candida albicans 11 (58) 36 - 77 4 (20) 7 - 42 0.023*
Non-albicans Candida spp.‖ 8 (42) 23 - 64 16 (80) 58 - 93 0.023*
Total Candida 19 (11) 7 - 16 20 (7) 5 - 11 0.234
CI = confidence interval; ESBL = extended-spectrum beta-lactamase; CRE = carbapenem-resistant Enterobacteriaceae; GNB = Gram-negative bacteria; MDR = multidrug resistant;  
XDR = extensively drug resistant; MRSA = methicillin-resistant S. aureus; CoNS = coagulase-negative staphylococcus; MR CoNS = methicillin-resistant coagulase-negative staphylococcus;  
VRE = vancomycin-resistant enterococcus; GPC = Gram-positive cocci.
*Statistically significant (p<0.05).
†Totals: 2013 N=178; 2017 N=270.
‡Groups are: total Gram-negative bacteria, total Gram-positive cocci, total Candida.
§2013: Klebsiella spp. (n=25), Escherichia coli (n=18), Enterobacter cloacae (n=5), Citrobacter spp. (n=2), Serratia marcescens (n=2), Morganella morganii (n=1), Proteus mirabilis (n=1),  
Providencia stuartii (n=1), Salmonella spp. (n=1); 2017: Klebsiella spp. (n=33), E. coli (n=21), E. cloacae (n=15), M. morganii (n=3), Proteus spp. (n=2), Citrobacter freundii (n=1),  
Pantoea agglomerans (n=1), Salmonella spp. (n=1).
¶2013: Acinetobacter baumannii (n=19), Pseudomonas spp. (n=13), Stenotrophomonas maltophilia (n=2), Burkholderia cepacia (n=1); 2017: Acinetobacter spp. (n=26), Pseudomonas spp. (n=18),  
S. maltophilia (n=3), Burkholderia spp. (n=14), Alkaligenes spp. (n=1).
‖2013: C. albicans (n=11), C. glabrata (n=5), C. parapsilosis (n=2), C. kefyr (n=1); 2017: C. glabrata (n=9), C. albicans (n=4), C. auris (n=5), C. krusei (n=2).
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is very difficult, and there are no simple criteria with sufficient 
specificity to assist with this decision.[27] On a positive note, the 
proportion of MRSA and VRE isolates decreased significantly. 
A similar decline in MRSA was also reported in another SA 
surveillance study.[23,28] CoNS are commonly implicated in catheter-
related bloodstream infections, and the CMJAH ICU/HCU treats 
these infections by removal of the infected catheter, without the use 
of vancomycin. Empirical use of vancomycin is therefore infrequent 
in this unit, which may have played a role in the decreased rates 
of MRSA and VRE. In 2017, all the Gram-positive cocci isolated 
were 99 - 100% susceptible to vancomycin and linezolid, making 
these agents appropriate for empirical therapy when Gram-positive 
organisms are suspected to be significant.
Although C. albicans remained the predominant yeast isolated 
overall, in both 2013 (64%) and 2017 (65%) it could have been 
considered a commensal in many cultures (e.g. the respiratory tract, 
urine and skin). There was a concerning increase in the percentage 
of MDR C. auris in 2017, from 0% to 17%. This is consistent with 
the dramatic increase of C. auris elsewhere in SA and globally over 
the past 4 years.[20] Candida spp. made up the minority of blood 
culture isolates in both years. However, as evidenced by numerous 
studies, blood cultures have low sensitivity, despite being the gold 
standard for the definitive diagnosis of candidaemia.[29] C. albicans 
was the predominant species isolated (58%) from blood cultures in 
2013, but of concern was that NAC predominated (80%) in 2017, 
which is in keeping with the global epidemiological shift of Candida 
spp.[20] As a result of this shift in epidemiology, the azoles are no 
longer the agents of choice for empirical therapy of Candida spp. 
infections. Susceptibilities to micafungin and amphotericin B were 
100% in 2017. These antifungals should be considered the agents 
of choice for empirical antifungal therapy in patients at high risk of 
invasive candidiasis, depending on the local availability and guideline 
recommendation.
This study provides the necessary/required cumulative antibiogram 
data for the CMJAH ICU/HCU, which can be used by clinicians to 
guide their empirical selection of antimicrobial therapy. The current 
NHLS LIS was not primarily designed as a research or surveillance 
tool,[30] so computer software limitations and data extraction methods 
need to be refined further in order to make the provision of 
annual cumulative antibiograms an achievable task by the clinical 
microbiology laboratory.
Study limitations
There were several limitations to this study. Firstly, because of the 
retrospective nature of the data analysis, real-time changes in AST 
or emergence of resistance are not reflected. Secondly, clinical data 
were not available to distinguish between hospital-acquired and 
community-acquired infections, and true infection v. colonisation. 
Thirdly, in order to reduce the bias that may be present in an all-
isolates approach, a first-isolate approach was used, as recommended 
by CLSI. This approach may, however, underestimate the resistance 
rate of nosocomial infections. Fourthly, the laboratory changed 
automated AST methods from Microscan in 2013 to Vitek 2 in 2017, 
and this could have affected AST results. In addition, the study was 
not able to analyse or report on colistin AST, as new testing methods 
were recommended in 2017 by CLSI and the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST), and these had 
not yet been routinely implemented by the microbiology laboratory 
during the study years. Lastly, tigecycline, amphotericin B and 
micafungin were not tested in 2013, so no comparison could be made 
for these antimicrobials.
Conclusions
Management of infections in ICU patients is an evolving challenge 
because of the ever-present threat of resistant isolates. The appropriate 
selection of  empirical  antibiotic therapy should be guided by ICU-
specific antibiograms. Based on this unit’s antibiogram, empirical 
antimicrobial therapy should always cover the Enterobacteriaceae, 
and the agent of choice would be ertapenem. Amikacin is 
recommended for empirical treatment of suspected pseudomonal 
infections. Additional empirical antimicrobial therapy for the Gram-
positive organisms is not routinely advocated, as the majority of 
isolates in this study were CoNS. In 2017, most S. aureus isolated 
were methicillin susceptible. Ertapenem is active against methicillin-
sensitive S. aureus and will offer coverage in the setting of empirical 
use. There was a low incidence of culture-proven candidaemia in 
this study, so empirical antifungal therapy with amphotericin B or 
micafungin would only be appropriate in patients at high risk of 
invasive candidiasis with accompanying clinical signs suggestive of 
such infections.
In order to adequately implement AMS as a tool to combat AMR 
in ICUs nationally, further prospective multicentre epidemiological 
studies are needed at multidisciplinary ICUs across SA.
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